Safety Assessment of the Food Enzyme D-Allulose 3-Epimerase from a Genetically Modified Corynebacterium

A regulatory baseline for allulose buyers

EFSA’s 2021 safety assessment (DOI 10.2903/j.efsa.2021.6870) gives buyers a reference point. This enzyme converts fructose into the special carbohydrate D-allulose. If you formulate reduced-sugar products, the regulatory baseline just got easier to explain.

Why this enzyme matters

Enzymes produce D-allulose from fructose. The enzyme D-allulose 3-epimerase catalyzes that conversion. The production strain is a genetically modified Corynebacterium. EFSA published the assessment to evaluate whether the food enzyme is safe for its intended use.

This matters for B2B buyers because safety opinions shape supply decisions. You need to know what regulators reviewed. You also need to know whether residual enzyme activity or DNA can show up in the final sweetener.

What the EFSA assessment covered

EFSA evaluated the enzyme preparation and the production organism. The assessment used total organic solids, or TOS, as the standard measure of enzyme dose. The enzyme processes fructose into D-allulose. During purification, processing removes TOS. The final D-allulose product contains no recombinant DNA.

Key findings from the safety assessment

The expert panel identified a no-observed-adverse-effect level of 1796 mg TOS per kilogram of body weight per day. That was the highest dose tested. No adverse effects appeared at that level. That matters.

Parameter	Finding
Food enzyme	D-allulose 3-epimerase
Production organism	genetically modified Corynebacterium
Key toxicity endpoint	NOAEL 1796 mg TOS/kg body weight/day
Carryover into product	TOS removed during processing
Recombinant DNA	not detected in D-allulose

The NOAEL gives formulators a number to work with. If your enzyme supplier provides TOS specifications, you can estimate safety margins for production scenarios. That is the kind of data point that helps when answering customer or regulatory questions.

What this means for formulators and ingredient buyers

First, the EFSA opinion supports supply chain confidence. A food enzyme with a published safety assessment is easier to defend than one without one. Buyers can point to an authoritative review instead of relying on vendor claims.

Second, TOS matters when comparing enzyme products. Two enzymes may run the same reaction. Their TOS loads can differ. Request TOS data from suppliers. Then compare products on that basis.

Third, the absence of TOS and DNA in the final D-allulose changes the conversation. The enzyme does its job during production and then leaves the stage. For customers focused on purity, that is a strong story. Your allulose is a purified carbohydrate end product.

That does not mean regulatory status is automatic everywhere. EFSA opinions apply to European food enzyme approvals. Other markets have their own frameworks. But a positive EFSA safety assessment often influences decisions elsewhere.

FAQ

What does TOS mean in enzyme safety studies?

TOS means total organic solids. It covers the enzyme protein plus other organic material from the production culture. Regulators use TOS to standardize doses in toxicity studies.

Does the enzyme stay in the finished allulose?

No. Processing removes TOS. The final D-allulose contains no detectable recombinant DNA.

What does the NOAEL of 1796 mg TOS/kg bw/day mean for me?

It means the highest dose tested produced no adverse effects in the study. Actual exposure depends on your use level and the TOS content of the enzyme preparation. Keep that exposure below the NOAEL reference.

A safety assessment with a clear NOAEL and no DNA carryover removes ambiguity from the buying decision. Allulose producers can point to an enzyme with a documented safety profile. Formulators now have one more documented reason to specify it with confidence.